

# John A Radford

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1388335/john-a-radford-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260  
papers

16,636  
citations

68  
h-index

124  
g-index

275  
ext. papers

19,183  
ext. citations

6.2  
avg, IF

5.85  
L-index

#	Paper	IF	Citations
260	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 507-16	59.2	1139
259	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2125-2132	2.2	641
258	Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1598-607	59.2	437
257	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2419-29	59.2	428
256	European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 317-24	2.2	404
255	Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5156-64	2.2	378
254	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 331-344	59.2	378
253	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet, The</i> , <b>2013</b> , 381, 1817-26	40	354
252	Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 206-14	9.7	353
251	Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 576-84	2.2	350
250	Imatinib mesylate (STI-571 Glivec <sup>®</sup> , Gleevec <sup>®</sup> ) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. <i>European Journal of Cancer</i> , <b>2003</b> , 39, 2006-2011	7.5	339
249	Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. <i>Lancet, The</i> , <b>2001</b> , 357, 1172-5	40	303
248	Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1316-23	2.2	301
247	Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , <b>2001</b> , 37, 870-7	7.5	293
246	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , <b>2015</b> , 126, 739-45	2.2	268
245	How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. <i>British Journal of Pharmacology</i> , <b>2011</b> , 163, 675-93	8.6	247
244	Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 1824-33	8.8	235

243	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , <b>2008</b> , 111, 5486-95	2.2	223
242	International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 423-9	2.2	220
241	Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3144-50	2.2	209
240	<i>Chlamydia psittaci</i> is variably associated with ocular adnexal MALT lymphoma in different geographical regions. <i>Journal of Pathology</i> , <b>2006</b> , 209, 344-51	9.4	196
239	Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4462-9	2.2	194
238	Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. <i>Human Reproduction</i> , <b>2001</b> , 16, 2056-60	5.7	177
237	Isolation of germ cells from human testicular tissue for low temperature storage and autotransplantation. <i>Fertility and Sterility</i> , <b>2001</b> , 75, 269-74	4.8	174
236	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i> , <b>2008</b> , 112, 2248-60	2.2	165
235	<sup>90</sup> Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1977-83	2.2	154
234	Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2105-12	2.2	151
233	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 51-7	4.4	149
232	Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 546-53	2.2	149
231	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , <b>2019</b> , 134, 1144-1153	2.2	148
230	The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. <i>Journal of Clinical Oncology</i> , <b>1988</b> , 6, 940-6	2.2	146
229	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , <b>2008</b> , 19, 233-41	10.3	144
228	Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1647-55	2.2	140
227	Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. <i>Blood</i> , <b>2005</b> , 105, 4576-82	2.2	138
226	Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1749-60	10.3	135

225	MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. <i>Journal of Pathology</i> , <b>2005</b> , 205, 293-301	9.4	129
224	Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4096-104	2.2	127
223	Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 1493-8	2.2	126
222	Phase I evaluation of a fully human anti-alpha <sub>v</sub> integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2128-35	12.9	124
221	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. <i>Blood</i> , <b>2012</b> , 119, 3698-704	2.2	118
220	Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 9208-18	2.2	115
219	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1433-1442	21.7	114
218	Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. <i>Journal of Clinical Oncology</i> , <b>1995</b> , 13, 134-9	2.2	113
217	Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , <b>2000</b> , 36, 61-7	7.5	108
216	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. <i>Blood</i> , <b>2016</b> , 127, 1531-8	2.2	105
215	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 319-331	21.7	103
214	A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. <i>Journal of Pathology</i> , <b>2009</b> , 217, 420-30	9.4	103
213	A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. <i>Leukemia</i> , <b>2010</b> , 24, 483-7	10.7	101
212	Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2745-52	2.2	100
211	Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2395-2404	2.2	100
210	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 544-551	2.2	99
209	Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1469-79	2.2	96
208	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , <b>2013</b> , 122, 1137-43	2.2	95

207	Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7985-93	2.2	90
206	Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. <i>Clinical Endocrinology</i> , <b>2001</b> , 55, 315-24	3.4	87
205	Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. <i>BMJ: British Medical Journal</i> , <b>1997</b> , 314, 343-6		83
204	Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. <i>Haematologica</i> , <b>2013</b> , 98, 611-4	6.6	81
203	Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>1996</b> , 14, 586-92	2.2	80
202	Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. <i>Blood</i> , <b>2008</b> , 111, 4764-70	2.2	79
201	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 216-221	4.4	77
200	Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. <i>British Journal of Haematology</i> , <b>2012</b> , 159, 154-63	4.5	74
199	Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction. <i>British Journal of Cancer</i> , <b>2000</b> , 82, 789-93	8.7	73
198	Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. <i>British Journal of Cancer</i> , <b>2008</b> , 98, 1403-14	8.7	72
197	Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. <i>Annals of Oncology</i> , <b>2008</b> , 19, 835-46	10.3	71
196	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology</i> , <b>2005</b> , 6, 773-9	21.7	71
195	The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 408-11	4.5	71
194	ChLVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2988-94	2.2	68
193	Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. <i>British Journal of Cancer</i> , <b>2002</b> , 87, 381-4	8.7	65
192	De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 282-7	2.2	64
191	Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1995</b> , 13, 1623-31	2.2	63
190	Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 565-73	4.5	62

189	Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , <b>1989</b> , 59, 276-82	8.7	62
188	Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3352-9 <sup>2.2</sup>		61
187	Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. <i>Blood</i> , <b>2007</b> , 109, 3922-8	2.2	60
186	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1530-1542	21.7	59
185	Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 346-53	4.5	57
184	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 790-800	21.7	56
183	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2405-2412	2.2	55
182	A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1923-1929	10.3	54
181	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , <b>2020</b> , 135, 735-742	2.2	54
180	Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. <i>Annals of Oncology</i> , <b>2011</b> , 22, 739-745	10.3	53
179	Fractionated <sup>90</sup> Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 212-8	2.2	50
178	Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. <i>British Journal of Cancer</i> , <b>1998</b> , 77, 1294-9	8.7	49
177	A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , <b>2001</b> , 84, 465-9	8.7	49
176	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6986-6994	12.9	49
175	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , <b>2016</b> , 101, 115-208	6.6	46
174	Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). <i>Oncologist</i> , <b>2014</b> , 19, 291-8 <sup>5.7</sup>		46
173	Restoration of fertility after treatment for cancer. <i>Hormone Research in Paediatrics</i> , <b>2003</b> , 59 Suppl 1, 21-3	3.3	44
172	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , <b>2021</b> , 137, 2634-2645	2.2	44



171	Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. <i>Journal of Clinical Oncology</i> , <b>1995</b> , 13, 2379-85	2.2	42
170	Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. <i>BioTechniques</i> , <b>2009</b> , 47, 587-96	2.5	41
169	Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. <i>British Journal of Cancer</i> , <b>1990</b> , 61, 749-54	8.7	41
168	Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. <i>European Journal of Cancer</i> , <b>1992</b> , 29A, 81-6	7.5	40
167	Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). <i>British Journal of Haematology</i> , <b>2014</b> , 164, 834-40	4.5	39
166	Current knowledge and future research directions in treatment-related second primary malignancies. <i>European Journal of Cancer, Supplement</i> , <b>2014</b> , 12, 5-17	1.6	39
165	Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. <i>British Journal of Cancer</i> , <b>2013</b> , 108, 2399-406	8.7	39
164	A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. <i>British Journal of Cancer</i> , <b>2001</b> , 85, 29-35	8.7	39
163	A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. <i>Journal of Clinical Oncology</i> , <b>1989</b> , 7, 1303-9	2.2	39
162	An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. <i>Toxicological Sciences</i> , <b>2014</b> , 140, 3-15	4.4	37
161	Risk of premature menopause after treatment for Hodgkin's lymphoma. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	37
160	The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. <i>Clinical Endocrinology</i> , <b>2000</b> , 52, 609-16	3.4	37
159	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2511-2516	10.3	36
158	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 719-25	8.7	36
157	Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , <b>1994</b> , 69, 379-81	8.7	36
156	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 583-586	4.5	35
155	The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. <i>British Journal of Cancer</i> , <b>2009</b> , 101, 582-8	8.7	35
154	Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 2493-8	2.2	35

153	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 570-8	4.5	34
152	Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. <i>British Journal of Radiology</i> , <b>2006</b> , 79, e40-4	3.4	34
151	Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>1998</b> , 16, 2601-12	2.2	34
150	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , <b>2018</b> , 5, e190-e200	14.6	33
149	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 334-42	4.5	33
148	Ultrastructural preservation of ovarian cortical tissue cryopreserved in dimethylsulfoxide for subsequent transplantation into young female cancer patients. <i>Ultrastructural Pathology</i> , <b>2004</b> , 28, 239-45	1.3	33
147	A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. <i>Haematologica</i> , <b>2018</b> , 103, 1351-1358	6.6	32
146	Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes. <i>British Journal of Cancer</i> , <b>1999</b> , 80, 1405-11	8.7	32
145	Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. <i>Blood</i> , <b>2016</b> , 128, 1107-1107	2.2	32
144	A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. <i>Annals of Oncology</i> , <b>2000</b> , 11, 861-5	10.3	31
143	Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 928-928	2.2	31
142	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , <b>2021</b> , 137, 637-645	2.2	31
141	Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). <i>Annals of Oncology</i> , <b>2006</b> , 17, 1546-52	10.3	30
140	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 668-672	4.5	29
139	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , <b>2016</b> , 101, e407-e410	6.6	28
138	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1732-1741	2.2	26
137	A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2863-9	1.9	26
136	Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 229-231	1.4	25



135	A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 886-90	4.5	25
134	YY1 expression predicts favourable outcome in follicular lymphoma. <i>Journal of Clinical Pathology</i> , <b>2011</b> , 64, 125-9	3.9	25
133	Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 95, 359-69	7	24
132	A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. <i>British Journal of Cancer</i> , <b>1993</b> , 67, 1385-90	8.7	24
131	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 123-123	2.2	24
130	Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. <i>Annals of Oncology</i> , <b>2000</b> , 11, 715-9	10.3	23
129	Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. <i>Journal of Molecular Diagnostics</i> , <b>2012</b> , 14, 223-32	5.1	22
128	Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. <i>British Journal of Cancer</i> , <b>1997</b> , 75, 110-5	8.7	22
127	Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. <i>Journal of Clinical Oncology</i> , <b>1991</b> , 9, 1446-52	2.2	22
126	Mitomycin C and vinblastine in the treatment of advanced breast cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1985</b> , 21, 1475-7		22
125	International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. <i>Annals of Oncology</i> , <b>1999</b> , 10, 13-9	10.3	21
124	Achieving pregnancy against the odds: successful implantation of frozen-thawed embryos generated by ICSI using spermatozoa banked prior to chemo/radiotherapy for Hodgkin's disease and acute leukaemia. <i>Human Reproduction</i> , <b>2001</b> , 16, 107-109	5.7	20
123	A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up. <i>Annals of Oncology</i> , <b>1991</b> , 2, 49-54	10.3	20
122	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , <b>2021</b> , 8, e410-e421	14.6	20
121	Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. <i>British Journal of Haematology</i> , <b>2005</b> , 129, 322-32	4.5	19
120	90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.. <i>Blood</i> , <b>2007</b> , 110, 643-643	2.2	19
119	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 860-867	4.5	18
118	A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. <i>Annals of Oncology</i> , <b>1996</b> , 7, 705-11	10.3	17

117	2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , <b>1996</b> , 7, 793-9	10.3	17
116	Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , <b>1999</b> , 24, 271-7	4.4	17
115	Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England. <i>Blood</i> , <b>2019</b> , 134, 767-767	2.2	17
114	Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: results of treatment in 184 patients. <i>Annals of Oncology</i> , <b>1994</b> , 5, 147-51	10.3	16
113	Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?. <i>Drugs</i> , <b>1992</b> , 44, 1-8	12.1	16
112	The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function. <i>British Journal of Cancer</i> , <b>1990</b> , 62, 127-32	8.7	16
111	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orchard Study (OMB110928). <i>Blood</i> , <b>2014</b> , 124, 630-630	2.2	16
110	PET-Directed Therapy for Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 392	59.2	15
109	An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. <i>British Journal of Cancer</i> , <b>1999</b> , 80, 444-7	8.7	15
108	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 104, 65-70	7	15
107	The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone. <i>Annals of Oncology</i> , <b>2014</b> , 25, 176-81	19.3	14
106	PLK1 and YY1 interaction in follicular lymphoma is associated with unfavourable outcome. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 764-7	3.9	14
105	The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1990</b> , 26, 144-6	3.5	14
104	Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a Negative FDG-PET Scan after 3 Cycles ABVD. <i>Blood</i> , <b>2008</b> , 112, 369-369	2.2	14
103	Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 471-479	4.5	13
102	Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1721-2	10.3	13
101	Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor. <i>European Journal of Cancer</i> , <b>1992</b> , 28, 105-12	7.5	13
100	Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE). <i>Cancer</i> , <b>1994</b> , 73, 470-5	6.4	12

99	The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1991</b> , 117 Suppl 4, S154-6	4.9	12
98	The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1796-9	1.9	11
97	Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). <i>Annals of Oncology</i> , <b>2010</b> , 21, 568-573	10.3	11
96	An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. <i>Annals of Oncology</i> , <b>1991</b> , 2, 423-9	10.3	11
95	Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. <i>Blood</i> , <b>2014</b> , 124, 4453-4453	2.2	11
94	Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 10028-10028	2.2	11
93	Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7555-7555	2.2	11
92	Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS7582-TPS7582	2.2	11
91	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 274-82	4.5	11
90	FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 504-513	4.5	11
89	Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 253-8	8.7	10
88	Treatment of relapsed Hodgkin's disease using a weekly chemotherapy of short duration: results of a pilot study in 20 patients. <i>Annals of Oncology</i> , <b>1991</b> , 2, 505-9	10.3	10
87	Monocytoid B cell lymphoma. <i>Journal of Clinical Pathology</i> , <b>1991</b> , 44, 39-44	3.9	10
86	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. <i>Blood Advances</i> , <b>2020</b> , 4, 203-206	7.8	10
85	Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1560-1561	59.2	9
84	QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma. <i>Journal of Molecular Diagnostics</i> , <b>2015</b> , 17, 402-11	5.1	9
83	A statistical framework for analyzing hypothesized interactions between cells imaged using multispectral microscopy and multiple immunohistochemical markers. <i>Journal of Pathology Informatics</i> , <b>2013</b> , 4, S4	4.4	9
82	Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8506-8506	2.2	9

81	Urinary 6-oxo prostaglandin F1 alpha in myocardial infarction. <i>British Medical Journal</i> , <b>1983</b> , 287, 727		8
80	Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 398-398	2.2	8
79	Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study. <i>Blood</i> , <b>2018</b> , 132, 2874-2874	2.2	8
78	90Y-Ibritumomab Tiuxetan (Zevalin <sup>®</sup> ) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients. <i>Blood</i> , <b>2010</b> , 116, 594-594	2.2	8
77	Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 224-235	4.5	8
76	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 212-221	4.5	7
75	Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 841-843	4.5	7
74	Treatment for early-stage hodgkin lymphoma: has radiotherapy had its day?. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3783-5	2.2	7
73	Autotransplantation of ovarian tissue and the risk of disease transmission. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2004</b> , 113 Suppl 1, S48-9	2.4	7
72	Semen collection from young cancer patients. <i>Human Fertility</i> , <b>2001</b> , 4, 131-4	1.9	7
71	Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1992</b> , 29, 252-5	3.5	7
70	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , <b>2018</b> , 132, 1618-1618	2.2	7
69	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 757-757	2.2	7
68	Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study. <i>Blood</i> , <b>2010</b> , 116, 3955-3955	2.2	7
67	Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000). <i>Blood</i> , <b>2011</b> , 118, 270-270	2.2	7
66	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , <b>2013</b> , 122, 764-764	2.2	7
65	Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. <i>Blood</i> , <b>2021</b> , 138, 213-220	2.2	7
64	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1586-1595	1.9	7

63	Burkitt's lymphoma of an ileal pouch following restorative proctocolectomy. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, E1596-7	4.5	6
62	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 2560-5	8.7	6
61	The role of computed tomography in the management of ovarian tumours of borderline malignancy. <i>Clinical Radiology</i> , <b>1997</b> , 52, 280-3	2.9	6
60	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 950-954	1.9	6
59	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , <b>2021</b> , 5, 640-648	7.8	6
58	Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231027	3.7	5
57	A randomized study of interferon $\beta$ versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. <i>Oncologist</i> , <b>2013</b> , 18, 1189	5.7	5
56	Pseudoautosomal linkage of familial Hodgkin's lymphoma: molecular analysis of a unique family with Leri-Weill dyschondrosteosis and Hodgkins lymphoma. <i>British Journal of Haematology</i> , <b>2003</b> , 121, 377-9	4.5	5
55	A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1991</b> , 117 Suppl 4, S139-40	4.9	5
54	The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>British Journal of Haematology</i> , <b>2011</b> , 129, 1716-1716	2.2	5
53	Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). <i>British Journal of Haematology</i> , <b>2021</b> , 193, 63-71	4.5	5
52	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8529-8529	2.2	4
51	Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, S278-S279	2	4
50	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. <i>Blood Advances</i> , <b>2021</b> , 5, 3387-3396	7.8	4
49	Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 452-454	4.4	3
48	Limited-stage disease: optimal use of chemotherapy and radiation treatment. <i>Hematology American Society of Hematology Education Program</i> , <b>2008</b> , 321-5	3.1	3
47	Autotransplantation of ovarian tissue. <i>Lancet, The</i> , <b>2001</b> , 358, 588	4.0	3
46	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , <b>2018</b> , 132, 4097-4097	2.2	3



45	Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000).. <i>Blood</i> , <b>2011</b> , 118, 3704-3704	2.2	3
44	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS8613-TPS8613	2.2	3
43	The perspectives of survivors of Hodgkin lymphoma on lung cancer screening: A qualitative study. <i>Health Expectations</i> , <b>2021</b> ,	3.7	3
42	. <i>Annals of Oncology</i> , <b>2000</b> , 11, 173-174	10.3	3
41	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NCRI phase II randomised LEGEND trial. <i>Annals of Hematology</i> , <b>2020</b> , 99, 105-112	3	3
40	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. <i>Hematological Oncology</i> , <b>2021</b> , 39, 185-195	1.3	3
39	Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma. <i>Clinical Oncology</i> , <b>2004</b> , 16, 53-7	2.8	2
38	Case report: enlargement of a mediastinal mass during treatment for Hodgkin's disease may be due to accumulation of fluid within thymic cysts. <i>Clinical Radiology</i> , <b>1995</b> , 50, 61-2	2.9	2
37	Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC). <i>Annals of Oncology</i> , <b>1993</b> , 4, 877-81	10.3	2
36	The iR2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 402-402	2.2	2
35	Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma.. <i>Blood</i> , <b>2008</b> , 112, 2002-2002	2.2	2
34	Consolidation Radiotherapy Is Associated with Improved Outcomes after Chemotherapy for Advanced Hodgkin Lymphoma: Analysis of Results from the UKLG LY09 Trial (ISRCTN97144519). <i>Blood</i> , <b>2008</b> , 112, 368-368	2.2	2
33	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy. <i>Blood</i> , <b>2011</b> , 118, 2718-2718	2.2	2
32	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , <b>2015</b> , 126, 2689-2689	2.2	2
31	Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study. <i>Blood</i> , <b>2016</b> , 128, 2980-2980	2.2	2
30	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS8613-TPS8613	2.2	2
29	Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 1015-1019	4.5	2
28	Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszczą Wyniki międzynarodowego, wielośrodkowego, badania II fazy z ibrutynibem (PCI-32765) [EHA Encore. <i>Acta Haematologica Polonica</i> , <b>2013</b> , 44, 314-318	0.4	1



27	XVI. Early stage Hodgkin lymphoma. <i>Hematological Oncology</i> , <b>2015</b> , 33 Suppl 1, 84-6	1.3	1
26	Ovarian Tissue Banking. <i>Journal of Mammalian Ova Research</i> , <b>2007</b> , 24, 8-13		1
25	Financial incentives and GPs: What about the impact on patient health?. <i>BMJ, The</i> , <b>2007</b> , 335, 60	5.9	1
24	A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma. <i>Clinical Oncology</i> , <b>2000</b> , 12, 153-7	2.8	1
23	A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial. <i>Blood</i> , <b>2018</b> , 132, 2956-2956	2.2	1
22	Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL).. <i>Blood</i> , <b>2006</b> , 108, 2723-2723	2.2	1
21	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , <b>2015</b> , 126, 517-517 <sup>2,2</sup>		1
20	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , <b>2016</b> , 128, 4194-4194	2.2	1
19	An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. <i>Ecancermedicalscience</i> , <b>2016</b> , 10, 608	2.7	1
18	Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3591-3601	2.2	1
17	Treatment of Hodgkin lymphoma in older patients. <i>Blood</i> , <b>2015</b> , 126, 2768-9	2.2	0
16	Reply to H.J.A. Adams et al and C. Kobe et al. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3325-3326	2.2	
15	019 Chemotherapy-induced cardiotoxicity: could a translational cardiac MRI model help identify patients at risk?. <i>Heart</i> , <b>2017</b> , 103, A16-A17	5.1	
14	Comparison of outcomes in studies of advanced Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3309; author reply 3309-10	2.2	
13	Autotransplantation of ovarian tissue. <i>Lancet, The</i> , <b>2001</b> , 358, 588	4.0	
12	Growth Factors and the Microenvironment <b>1993</b> , 36-43		
11	The management of Hodgkin's disease. <i>Annals of Oncology</i> , <b>1993</b> , 4, 417-21	10.3	
10	YY1 Expression Predicts Survival in Follicular and Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , <b>2006</b> , 108, 2033:2033		

- 9 Clinical Measurement of Prognostic Immune Signature in Follicular Lymphoma by RT-PCR Based Gene Expression Profiling and Immunohistochemistry Demonstrates Favourable T-Cell and Unfavorable Macrophage Infiltration.. *Blood*, **2007**, 110, 359-359 2.2
- 8 A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. *Blood*, **2014**, 124, 4481-4481 2.2
- 7 Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial. *Blood*, **2015**, 126, 1516-1516 2.2
- 6 Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. *Blood*, **2015**, 126, 1499-1499 2.2
- 5 Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial. *Blood*, **2016**, 128, 2978-2978 2.2
- 4 A Blood Borne Biomarker of Cell Death (nucleosomal DNA) Is An Early Predictor of End of Treatment Response to Chemotherapy in Lymphoma. *Blood*, **2008**, 112, 4828-4828 2.2
- 3 Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET Negative After 3 Cycles of ABVD Chemotherapy.. *Blood*, **2008**, 112, 1449-1449 2.2
- 2 Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000). *Blood*, **2013**, 122, 1814-1814 2.2
- 1 Letter comments on a published article in the New England Journal of Medicine. *European Journal of Cancer*, **2018**, 104, 250-251 7.5